TuHURA Biosciences (HURA) Income from Continuing Operations (2010 - 2012)
TuHURA Biosciences (HURA) posted quarterly Income from Continuing Operations of 7405.0 for Q4 2012, up 62.24% year-over-year from 4564.16 in Q1 2012, and down 78.22% quarter-over-quarter from 4155.0 in Q3 2012.
TuHURA Biosciences (HURA) Income from Continuing Operations (2010 - 2012) Analysis & Trends
TuHURA Biosciences' Income from Continuing Operations history runs 3 years deep, the most recent figure standing at 7405.0 for Q4 2012.
- In Q4 2012, Income from Continuing Operations rose 62.24% year-over-year to 7405.0; the TTM figure through Dec 2012 stood at 39808.0 (down 16.64% YoY), while the FY2012 annual figure was 18885.0, up 43.01% from the prior year.
- Income from Continuing Operations for Q4 2012 stood at 7405.0, down from 4155.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 3827.0 in Q1 2011, with the low at 23526.0 in Q1 2012.
- The 3-year median for Income from Continuing Operations is 7118.0 (2011), against an average of 9641.4.
- Peak annual rise in Income from Continuing Operations reached 62.24% in 2012, while the deepest fall reached 514.74% in 2012.
- TuHURA Biosciences' Income from Continuing Operations stood at 14568.0 in 2010, then slumped by 34.62% to 19612.0 in 2011, then soared by 62.24% to 7405.0 in 2012.
- Business Quant data shows HURA's Income from Continuing Operations at 7405.0 in Q4 2012, 4155.0 in Q3 2012, and 4722.0 in Q2 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | TuHURA Biosciences | 37.61 Mn | 37.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | -7,405.00 |
| Sep 30, 2012 | -4,155.00 |
| Jun 30, 2012 | -4,722.00 |
| Mar 31, 2012 | -23,526.00 |
| Dec 31, 2011 | -19,612.00 |
| Sep 30, 2011 | -3,858.00 |
| Jun 30, 2011 | -6,831.00 |
| Mar 31, 2011 | -3,827.00 |
| Dec 31, 2010 | -14,568.00 |
| Sep 30, 2010 | -7,910.00 |